-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師總結了他們的觀點如下：我們將12個月目標價上調5美元至22美元，並採用2.0倍的企業價值/營收倍數（EV/Revenue）對2026年業績進行估值，該倍數低於其三年曆史平均水平2.5倍。我們將2026年每股盈餘（EPS）預期下調0.01美元至3.09美元，並將2027年每股盈餘預期上修0.14美元至3.45美元。報告指出，汽車銷售環境疲軟，導致試用用戶數量減少，並影響了用戶獲取，尤其是在去年受資費政策推動的汽車銷售提前之後。自費用戶的轉換率略有下降，尤其是在年輕購車者開始試用時，二手車用戶的轉換率仍低於新車用戶。預計訂閱用戶數量將同比略有下降，管理層警告稱，由於汽車銷售和配套訂閱率的不確定性，持續存在壓力，因此拒絕改變今年的訂閱用戶數量預期。
Related Articles
Mining & Metals
PJX Resources Adopting Semi-Annual Financial Reporting
$PJX.V
Australia
Lattice Semiconductor to Acquire AMI for $1.65 Billion in Cash and Stock From THL Partners
Lattice Semiconductor (LSCC) agreed to acquire AMI, a cloud and AI-server management software company, for $1.65 billion in cash and stock from THL Partners.The purchase includes $1 billion in cash and $650 million in Lattice stock. The acquisition is expected to close in Q3, subject to regulatory approvals and other conditions, Lattice said Monday in a statement.The transaction is expected to be accretive to gross margin, free cash flow and earnings per share on an adjusted basis, and AMI is projected to generate more than $200 million in revenue in 2026, Lattice said.Lattice shares rose 0.4% in after-hours trading after gaining 3.8% in the regular session.
$LSCC
Research
Research Alert: Vertex Reports Mixed Q1, Reaffirms Full-year 2026 Financial Guidance
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Vertex delivered mixed Q1 results with revenue of $2.99B (+8% Y/Y) falling $10M short of expectations, though non-GAAP EPS of $4.47 (+10% Y/Y) beat the consensus by $0.16. The quarter demonstrated successful execution of VRTX's multi-product launch strategy, with ALYFTREK generating $424.4M (vs. $53.9M prior year), CASGEVY contributing $42.9M (+202% Y/Y), and JOURNAVX adding $29.0M in its second commercialization year. Recent FDA label extensions for ALYFTREK and TRIKAFTA expanded CF patient eligibility to ~95% in the U.S., adding roughly 800 more patients. VRTX maintained its 2026 guidance unchanged with total revenue expectations of $12.95B-$13.1B and non-CF product revenue of $500M or greater. We view the operating leverage positively, with revenue growth outpacing expense increases, and believe the diversification strategy beyond CF continues to gain traction with meaningful contributions from newly launched therapies across multiple therapeutic areas.
$VRTX